Lymphoblastic lymphoma (LBL) was first described by Barcos and Lukes [1] in 1975 and was termed convoluted T-cell lymphoma. Nathwani and colleagues [2] in 1976 redefined LBL as a disease having discreet pathologic and clinical features from diffuse, small cleaved cell lymphoma. In 1982, the National Cancer Institute sponsored study of 1175 adult patients [3] gave rise to the international Working Formulation of non-Hodgkin’s lymphomas, which recognized LBL as one of its 10 discreet clinical entities. Approximately 4% of patients in the above study were classified as having this high grade lymphoma. As the incidence of non-Hodgkin’s lymphomas in the United States is about 1:10,000 persons annually [4], roughly 1200 individuals would be expected to be diagnosed with LBL in the United States each year. Despite the rarity of this condition, an understanding of the clinical, pathologic, and therapeutic principles used in the management of LBL is important, not only for LBL patients, but also for those with related disorders, such as other intermediate and high grade non-Hodgkin’s lymphomas and Tcell acute lymphoblastic leukemia (T-ALL).


Acute Lymphoblastic Leukemia Mediastinal Mass Cytosine Arabinoside Lymphoblastic Lymphoma Memorial Sloan Kettering Cancer Center 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barcos MGP, Lukes RJ: Malignant lymphoma of convoluted lymphocytes: a new entity of possible T-cell type. In L Sinks, J Gooden, eds. Conflicts of Childhood Cancer: An Evaluation of Current Management. New York: Alan R. Liss, 1975, pp 145–178.Google Scholar
  2. 2.
    Nathwani BN, Kim H, Rappaport H: Malignant lymphoblastic lymphoma. Cancer 38:968–983, 1976.CrossRefGoogle Scholar
  3. 3.
    Rosenberg SA: The Non-Hodgkin’s Lymphoma Pathologic Classification Project. The National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Cancer 49:2112–2135, 1982.CrossRefGoogle Scholar
  4. 4.
    Devita VT, Jaffe ES, Mauch P, et al.: Lymphocytic lymphomas. In VJ Devita, S Hellman, SA Rosenberg, eds. Cancer Principles & Practice of Oncology. Philadelphia: JB Lippincott, 1987, p 1741.Google Scholar
  5. 5.
    Ueshima Y, Rowley JD, Variakojis D, et al.: Cytogenetic studies on patients with chronic T-cell leukemia/lymphoma. Blood 63:1028–1034, 1983.Google Scholar
  6. 6.
    Smith SD, Morgan R, Germmell R, et al.: Clinical and biologic characterization of T-cell neoplasia with rearrangement of chromosome 7 band 34. Blood 71:395–402, 1988.PubMedGoogle Scholar
  7. 7.
    Clarkson B: New pharmacologic approaches to treatment leukemia. Semin Hematol 28(Suppl 4):99–115, 1991.PubMedGoogle Scholar
  8. 8.
    Pellici P-G, Knowles D, Magrath I, et al.: Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic sporadic forms of Burkitt’s lymphoma. Proc Natl Acad Sci USA 83:2984–2988, 1986.CrossRefGoogle Scholar
  9. 9.
    Shebani K, Nathwani BN, Winberg CD, et al.: Antigenically defined subgroups of lymphoblastic lymphoma. Cancer 60:183–190, 1987.CrossRefGoogle Scholar
  10. 10.
    Weiss LM, Bindl JM, Picozzi VJ: Lymphoblastic lymphoma: an immunophenotypic study of 26 cases in comparison with T-cell acute lymphoblastic lymphoma. Blood 67:464–478, 1986.Google Scholar
  11. 11.
    Nosaka T, Ohno H, Doi S, et al.: Phenotypic conversion of T lymphoblastic leukemia to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. J Clin Invest 81:1824–1828, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Weiss LM, Strickler JG, Medeiros LJ, et al.: Proliferative rates of non-Hodgkin’s lymphomas as assessed by Ki-67 antibody. Hum Pathol 18:1155–1159, 1987.PubMedCrossRefGoogle Scholar
  13. 13.
    Srivastava BI: Establishment of a suppressor T-cell line showing autocrine growth from a patient with lymphoblastic lymphoma. Proceedings of the Annual Meeting of the American Association for Cancer Research 29, abstract 1739, 1988.Google Scholar
  14. 14.
    Magrath IT: Malignant non-Hodgkin’s lymphomas in children. Hematol Oncol Clin North Am 1:577–602, 1987.PubMedGoogle Scholar
  15. 15.
    Coleman CN, Picozzi VJ, Cox RS, et al.: Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637, 1986.PubMedGoogle Scholar
  16. 16.
    Keidan AJ, Catovsky D, Tavares De Castro JC, et al.: Hypereosinophilic syndrome preceding T-cell lymphoblastic lymphoma. Clin Lab Haemotol 7:83–88, 1985.CrossRefGoogle Scholar
  17. 17.
    Pistoia V, Roncella S, De Celle PF, et al.: Emergence of a B-cell lymphoblastic leukemia in a patient with B-cell citronic lymphocytic leukemia: evidence for the single cell origin of the two tumors. Blood 78:797–804, 1991.PubMedGoogle Scholar
  18. 18.
    Jarczk K, Krawcyzk-Kvlis M, Duraj M, et al.: Lymphoblastic lymphoma in a woman with chronic granulocytic leukemia. Folia Haematol (Leipz) 112:391–396, 1985.Google Scholar
  19. 19.
    Childs CC, Chrystal GS, Strauchen JA: Bipitenotypic lymphoblastic lymphoma. An unusual tumor with lymphocytic and granulocytic differentiation. Cancer 57:1019–1023, 1986.PubMedCrossRefGoogle Scholar
  20. 20.
    Cossman J, Chused T, Fisher R, et al.: Diversity of immunologic phenotypes of lymphoblastic lymphoma. Cancer 43:4486–4490, 1983.Google Scholar
  21. 21.
    Foon KA, Todd RF: Immunologic classification of leukemia and lymphoma. Blood 68:1–31, 1986.PubMedGoogle Scholar
  22. 22.
    Borowitz MJ, Fallita JM: Leukemias and lymphomas of thymic differentiation. Clin Lab Med 8:119–134, 1988.PubMedGoogle Scholar
  23. 23.
    Goutefangea SC, Bensussan A, Baumsell L: Study of the CD3 associated T-cell receptors reveals further differences between T-cell acute lymphoblastic lymphoma and leukemia. Blood 75:1931–1934, 1991.Google Scholar
  24. 24.
    Kaneko Y, Frizzera G, Skikano T, et al.: Chromosomal and immunophenotypic patterns in T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). Leukemia 3:886–892, 1989.PubMedGoogle Scholar
  25. 25.
    Voakes JB, Jones SE, McKezvey EM: The chemotherapy of lymphoblastic lymphoma. Blood 57:186–188, 1981.PubMedGoogle Scholar
  26. 26.
    Liang R, Todd D, Chan TK, et al.: Intensive therapy for adult lymphoblastic lymphoma. Cancer Chemother Pharmacol 29:80–82, 1991.PubMedCrossRefGoogle Scholar
  27. 27.
    Weinstein JH, Vance ZB, Jaffe N, et al.: Improved prognosis for patients with mediastinal lymphoblastic lymphoma. Blood 53:687–694, 1979.PubMedGoogle Scholar
  28. 28.
    Anderson JR, Wilson JR, Jenkin RD, et al.: The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308:559–565, 1983.PubMedCrossRefGoogle Scholar
  29. 29.
    Levine AM, Forman ST, Meyer DR, et al.: Successful therapy of convoluted T-lymphocyte lymphoma in the adult. Blood 61:92–98, 1982.Google Scholar
  30. 30.
    Slater DE, Mertelsmann R, Kozimer B, et al.: Lymphoblastic lymphoma in adults. J Clin Oncol 4:1628–1637, 1986.Google Scholar
  31. 31.
    Dahl GV, Rivera G, Pui CH: A novel treatment of childhood lymphoblastic non-Hodgkin’s lymphoma: early and intermittent use of teniposide plus cytarabine. Blood 66:110–114, 1985.Google Scholar
  32. 32.
    Amylon M, Murphy S, Pullen J: Treatment of lymphoid malignancies according to immune phenotype: preliminary results in T-cell disease. Proc Am Soc Clin Oncol 7:225, 1988.Google Scholar
  33. 33.
    Kersey J, Krailo M, Meadows A, et al.: Childhood lymphoblastic lymphoma (LL): a randomized trial comparing LSA-2 to ADCOMP. Proc Am Soc Clin Oncol 10:289, 1991.Google Scholar
  34. 34.
    Colgan J, Anderson J, Glick J, et al.: Treatment of lymphoblastic lymphoma in adults. Proc Am Soc Clin Oncol 6:194, 1987.Google Scholar
  35. 35.
    Picozzi VJ, Coleman CN: Lymphoblastic lymphoma. Semin Oncol 17:96–103, 1990.PubMedGoogle Scholar
  36. 36.
    Appelbaum FR, Sullivan KM, Buckmer CD, et al.: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 5:1344–1347, 1987.Google Scholar
  37. 37.
    Satini G, Congiu AM, Coser P, et al.: Autologous bone marrow transplantation for adult advanced stage lymphoblastic lymphoma in 1st CR. A study of the NHL CSG. Leukemia 5(Suppl l):42–45, 1991.Google Scholar
  38. 38.
    Milpied N, Ifrah N, Kuentz M, et al.: Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 73:82–87, 1989.PubMedCrossRefGoogle Scholar
  39. 39.
    Wong KK, Sweet DL, Variakojis D: The treatment of lymphoblastic lymphoma with antithymocyte globulin. Cancer 50:57–61, 1982.PubMedCrossRefGoogle Scholar
  40. 40.
    Winick N, Buchanan G, Murphy SB, et al.: Drexycoformycin in the treatment of T-cell lymphoblastic leukemia (T-ALL) early in second remission. Proc Am Soc Clin Oncol 6:152, 1987.Google Scholar
  41. 41.
    Kantarjian H, Estey E, O’Brien S, et al.: Intensive chemotherapy with mitoxantrone and high dose cytosine ararinoside followed by granulocyte-macrophage colony stimulating factor in the treatment of patients with acute lymphocytic leukemia (ALL). Blood 78(Suppl 1):50, 1991.Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Vincent J. PicozziJr.

There are no affiliations available

Personalised recommendations